Changes to the Pharmaceutical Benefits Advisory Committee

---

• 1.
• Meddling with drugs [editorial]. The Sydney Morning Herald 2000; 2 Dec.
• 2.
• Drugs scheme has its benefits [editorial]. Australian Financial Review 2000; 13 Dec.
• 3.
• The Auditor-General Audit Report No. 12, 1997-98: Peformance Audit -- Pharmaceutical Benefits Scheme, Department of Health and Family Services. <http://www.anao.gov.au> (accessed February 2001).
• 4.
• Cookson R. ASTEC non-EU case study on Australia. London: LSE Health, London School of Economics, 2000 <http://www.lse.ac.uk/Depts/lse_health/res_ projects/oz.pdf> (accessed February 2001)
• 5.
• Witcher SK. In the land down under, a model for national drug insurance. The Wall Street Journal 2000; 6 Sept.
• 6.
• M-TAG Pty Ltd. Report on the Australian System of Pharmaceutical Financing and Delivery. Vol 1: Efficiency and equity implications of public versus private funding of pharmaceuticals. Chatswood, NSW: Medical Technology Assessment Group, Nov 1999.
• 7.
• PBS expenditure and prescriptions. <www.health.gov.au/haf/docs/ pbbexp/index.htm> (accessed February 2001).
• 8.
• National Health Act (1953, amended 1987). <http://www.austlii.edu.au> (accessed February 2001).
• 9.
• Pfizer Pty Ltd v Birkett. Federal Court of Australia 20 March 2000. <http://www.fedcourt.gov.au/judgments/judgmts.html> (accessed February 2001).
• 10.
• Moynihan R. A dose of drama in debate on drugs. Australian Financial Review 2000; 8 Dec.
• 11.
• Angell M. The Pharmaceutical Industry -- to whom is it accountable? N Engl J Med 2000; 342: 1902-1904.
• 12.
• Mullins CD, Ogilvie S. Emerging standardization in pharmaco-economics. Clin Ther 1998; 20: 1194-1202.
• 13.
• Yamey G. NICE to rule on influenza flu drug zanamivir. BMJ 1999; 319: 937.
• 14.
• Harris G. Drug firms, stymied in the lab, become marketing machines. The Wall Street Journal 2000; 6 July.
• 15.
• le CarrŽ J. The biggest pushers of all. The Spectator (London) 2000; 16 Dec.
• 16.
• Schoofs M. Glaxo attempts to block access to generic AIDS drugs in Ghana. The Wall Street Journal 2000; 1 Dec.
• 17.
• Gellman G. A turning point that left millions behind. Washington Post 2000; 28 Dec.
• 18.
• Korcok M. Cheap prescription drugs creating new brand of US tourist in Canada, Mexico. CMAJ 2000; 162: 1869-1870.
• 19.
• Silverman E. Drug makers on attack in Maine. The Star Ledger (New Jersey) 2000; 24 Sep.
• 20.
• Shuchman M. Drug company threatens legal action over Canadian guidelines. BMJ 1999; 319: 1388.
• 21.
• Nathan DG, Weatherall DJ. Academia and industry: lessons from the unfortunate events in Toronto. Lancet 1999; 353: 771-772.
• 22.
• Rennie D. Thyroid storm. JAMA 1997; 277: 1238-1243.
• 23.
• Dyer C. Viagra guidance declared unlawful. BMJ 1999; 318: 1509.
• 24.
• McNeil DG. Drug companies and the Third World: a case study in neglect. The New York Times; 2000: 21 May.
• 25.
• Silverstein K. Millions for Viagra. Pennies for the poor. The Toronto Star 1999; 13 Aug.
• 26.
• Mansfield P. Sickening sales pitch of the drug marketers. The Sydney Morning Herald 2000; 3 July.
• 27.
• Department of Health and Aged Care. Pharmaceutical Benefits Branch. <http://www.health.gov.au/haf/docs/pbacrec.htm> (accessed February 2001).
• 28.
• Angell M. Is academic medicine for sale? N Engl J Med 2000; 342: 1516-1518.